Table 3 Comparison between fasting and random lipid profile of the participants and its relation with patient characteristics
Characteristics | Fasting | Random | Absolute difference | Diff (%) | p-value for Diff (%)* |
|---|---|---|---|---|---|
Median (Q1 –Q3) | Median (Q1 –Q3) | Median (Q1 –Q3) | |||
TG | |||||
Sex | |||||
Male | 188.5 (150 to 243) | 230 (180 to 286) | 25 (8.5 to 62) | 13.72% | 0.498 |
Female | 180 (149 to 246) | 223 (178 to 289) | 26 (9 to 65) | 13.81% | |
Age | |||||
< 45 | 180 (155 to 241) | 223 (178 to 282) | 28 (8 to 62) | 15.06% | 0.507 |
≥ 45 | 190 (145 to 249) | 230 (180 to 289) | 25 (9 to 65) | 12.5% | |
DM drug | |||||
Insulin | 195 (150 to 252) | 230 (180 to 290) | 25 (7 to 66) | 12.65% | 0.482 |
OHA | 180 (149 to 241) | 223 (178 to 286) | 26 (9 to 62) | 14.21% | |
BMI | |||||
Normal | 180 (143 to 250) | 217 (167 to 288) | 20 (6 to 54) | 11.43% | 0.364 |
Overweight | 180 (150 to 248) | 230 (180 to 291) | 27 (9 to 66) | 14.21% | |
Obese | 190 (155 to 241) | 224 (180 to 280) | 26 (9 to 62) | 14.28% | |
Lipid lowering agent | |||||
No | 191 (145 to 266) | 230 (180 to 313) | 25 (9.4 to 64.5) | 12.68% | 0.500 |
Yes | 180 (155 to 240) | 225 (178 to 270) | 26 (8 to 64) | 14.28% | |
LDL-C | |||||
Sex | |||||
Male | 91 (65.5 to 120) | 89 (62 to 119) | -1 (-12.38 to 6) | -1.03% | 0.457 |
Female | 83 (53 to 120) | 83 (56 to 121) | 0 (-8 to 8) | 0.00% | |
Age | |||||
< 45 | 79 (53 to 113) | 79 (51 to 114) | -2 (-10 to 8) | -0.19% | 0.502 |
≥ 45 | 95 (66 to 129) | 95 (65 to 126) | -1 (-9 to 6) | -0.95% | |
DM drug | |||||
Insulin | 79 (60 to 115) | 79 (59 to 114) | -1 (-10 to 10) | 0.61% | 0.512 |
OHA | 92 (59 to 121) | 91 (57 to 123) | -1 (-9 to 6) | -0.87% | |
BMI | |||||
Normal | 102 (79 to 133) | 107 (83 to 130) | 1 (-5 to 8) | 1.33% | 0.472 |
Overweight | 77 (53 to 114) | 76 (52 to 113) | -2 (-11 to 7) | -1.75% | |
Obese | 93 (63 to 123) | 90 (59 to 126) | 0 (-10 to 6) | 0.00% | |
Lipid lowering agent | |||||
No | 110 (89 to 139) | 112 (89 to 139) | 0 (-7 to 6) | 0.00% | 0.520 |
Yes | 68 (49 to 98) | 67 (49 to 95) | -1 (-11 to 9) | -1.05% | |
HDL-C | |||||
Sex | |||||
Male | 41 (35 to 46) | 40 (34 to 46.85) | 0 (-3 to 3) | 0.00% | 0.458 |
Female | 43 (37 to 49) | 43 (37 to 50) | 0 (-4 to 4) | 0.00% | |
Age | |||||
< 45 | 43 (36.6 to 49) | 43 (36 to 50) | 0 (-4 to 5) | 0.00% | 0.526 |
≥ 45 | 41 (36 to 48) | (35 to 48) | -1 (-3 to 3) | -2.02% | |
DM drug | |||||
Insulin | 42.8 (36 to 48) | 43 (36 to 49) | 0 (-4 to 4) | 0.00% | 0.532 |
OHA | 42 (36 to 48) | 41 (35 to 48) | -1 (-4 to 3) | -1.98% | |
BMI | |||||
Normal | 41 (36 to 47) | 40 (34 to 47) | -1 (-4.2 to 3) | -3.33% | 0.522 |
Overweight | 43 (36 to 49) | 43 (36 to 49) | 0 (-4 to 4) | 0.00% | |
Obese | 42 (36 to 48) | 41 (36 to 48) | 0 (-3 to 3) | 0.00% | |
Lipid lowering agent | |||||
No | 40 (35 to 47) | 40 (35 to 45) | -1 (-3 to 3) | -2.25% | 0.466 |
Yes | 43 (37 to 49) | 45 (36 to 50) | 0 (-4 to 5) | 0.00% | |
TC | |||||
Sex | |||||
Male | 192 (166 to 220) | 192 (165 to 225) | 0 (-10 to 10) | 0.00% | 0.442 |
Female | 198 (171 to 230) | 210 (177 to 237) | 2 (-8 to 19) | 1.25% | |
Age | |||||
< 45 | 204 (182 to 231) | 210 (184 to 231) | 1 (-11 to 17) | 0.57% | 0.502 |
> 45 | 188 (158 to 220) | 192 (160 to 225) | 1 (-7 to 11) | 0.48% | |
DM drug | |||||
Insulin | 201 (160 to 231) | 205 (165 to 235) | 0 (-10 to 15) | 0.00% | 0.482 |
OHA | 192 (170 to 221) | 198 (174 to 229) | 1 (-8 to 12) | 0.71% | |
BMI | |||||
Normal | 191 (160 to 220) | 192 (166 to 225) | 1 (-6 to 10) | 0.74% | 0.490 |
Overweight | 198 (174 to 230) | 210 (176 to 235) | 2 (-10 to 19) | 1.32% | |
Obese | 195 (168 to 225) | 199 (167 to 222) | 0 (-10 to 10) | 0.00% | |
Lipid lowering agent | |||||
No | 190 (166 to 220) | 194 (168 to 222) | 1 (-7 to 10) | 0.61% | 0.500 |
Yes | 201 (174 to 230) | 210 (170 to 235) | 1 (-10 to 19) | 0.43% |